{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:20Z","timestamp":1791605840262,"version":"4.3.4"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01123-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:48:08Z","timestamp":1771933688000},"page":"239-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Natriuretic peptides and cardiac troponins in hypertension and heart failure: A contemporary review of the evidence"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-5881","authenticated-orcid":false,"given":"Anping","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7439","authenticated-orcid":false,"given":"Gianfranco","family":"Parati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"1123_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet (London, England). 2021;398:957\u201380.","journal-title":"Lancet (London, England)"},{"key":"1123_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027852","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: A secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc. 2023;12:e027852.","journal-title":"J Am Heart Assoc"},{"key":"1123_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","volume":"5","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: Contemporary update. JACC. Heart Failure. 2017;5:543\u201351.","journal-title":"JACC. Heart Failure"},{"key":"1123_CR4","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1161\/HYPERTENSIONAHA.121.16503","volume":"77","author":"K Raby","year":"2021","unstructured":"Raby K, Rocco M, Oparil S, Gilbert ON, Upadhya B. Heart failure primary prevention: What Does SPRINT Add?: Recent advances in hypertension. Hypertension (Dallas, Tex. : 1979). 2021;77:1804\u201314.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR5","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A report of the american college of Cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:e263\u2013e421.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR6","unstructured":"Zhang S, Tian Z, Xu D, Song Z, Wang Z, Zhang Y, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024. Zhonghua xin xue guan bing za zhi 2024;52:235\u201375."},{"key":"1123_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: An underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022;45:1670\u201390.","journal-title":"Diabetes Care"},{"key":"1123_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352\u201380.","journal-title":"Eur J Heart Fail"},{"key":"1123_CR9","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"1123_CR10","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 2025;152:e114\u2013e218."},{"key":"1123_CR11","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1123_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"1123_CR13","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. In: Guideline for the pharmacological treatment of hypertension in adults. World Health Organization \u00a9 World Health Organization 2021.: Geneva, 2021."},{"key":"1123_CR14","doi-asserted-by":"crossref","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (Dallas, Tex. : 1979) 2020;75:1334\u201357.","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"1123_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/ehjqcco\/qcae110","volume":"11","author":"QF Chen","year":"2025","unstructured":"Chen QF, Chen L, Katsouras CS, Liu C, Shi J, Liang D, et al. Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021. Eur Heart J Qual Care Clin Outcomes. 2025;11:493\u2013509.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1123_CR16","doi-asserted-by":"crossref","unstructured":"Yan S, Deng P, Chai K, Wang S, Hu K, Yang J, Wang H Global, regional, and national burden of heart failure and its risk factors between 1990-2021 and projections to 2050: An analysis of the global burden of disease study. Eur Heart J Qual Care Clin Outcomes. 2025;11:1144\u201354.","DOI":"10.1093\/ehjqcco\/qcaf054"},{"key":"1123_CR17","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: A report of the heart failure society of America. J Card Fail. 2023;29:1412\u201351.","journal-title":"J Card Fail"},{"key":"1123_CR18","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2468-2667(19)30108-2","volume":"4","author":"CA Lawson","year":"2019","unstructured":"Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: A population-based study. Lancet Public Health. 2019;4:e406\u2013e420.","journal-title":"Lancet Public Health"},{"key":"1123_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008406","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Chai K, Du M, Wang S, Cai JP, Li Y, et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis. Circ Heart Fail. 2021;14:e008406.","journal-title":"Circ Heart Fail"},{"key":"1123_CR20","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats A Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res. 2022.","DOI":"10.1093\/cvr\/cvac013"},{"key":"1123_CR21","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/eurheartj\/ehaf323","volume":"46","author":"M Darvish","year":"2025","unstructured":"Darvish M, Shakoor A, Feyz L, Schaap J, van Mieghem NM, de Boer RA, et al. Heart failure: Assessment of the global economic burden. Eur Heart J. 2025;46:3069\u201378.","journal-title":"Eur Heart J"},{"key":"1123_CR22","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1001\/jama.2023.5942","volume":"329","author":"P Joseph","year":"2023","unstructured":"Joseph P, Roy A, Lonn E, St\u00f6rk S, Floras J, Mielniczuk L, et al. Global variations in heart failure etiology, management, and outcomes. JAMA. 2023;329:1650\u201361.","journal-title":"JAMA"},{"key":"1123_CR23","first-page":"n461","volume":"372","author":"J Tromp","year":"2021","unstructured":"Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, et al. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ (Clinical Research ed.). 2021;372:n461.","journal-title":"BMJ (Clinical Research ed.)"},{"key":"1123_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jacc.2017.06.046","volume":"70","author":"TM Stokke","year":"2017","unstructured":"Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA, et al. Geometry as a confounder when assessing ventricular systolic function: Comparison between ejection fraction and strain. J Am Coll Cardiol. 2017;70:942\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ejhf.154","volume":"16","author":"C Russo","year":"2014","unstructured":"Russo C, Jin Z, Elkind MS, Rundek T, Homma S, Sacco RL, Di Tullio MR. Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community-based cohort. Eur J Heart Fail. 2014;16:1301\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1123_CR26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/HJH.0b013e3282fe1d3d","volume":"26","author":"G Tocci","year":"2008","unstructured":"Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008;26:1477\u201386.","journal-title":"J Hypertens"},{"key":"1123_CR27","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1123_CR28","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921\u201330.","journal-title":"N Engl J Med"},{"key":"1123_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: An open-label, blinded-outcome, randomised trial. Lancet (London, England). 2024;404:245\u201355.","journal-title":"Lancet (London, England)"},{"key":"1123_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1123_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"1123_CR32","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020."},{"key":"1123_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"1123_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1123_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"1123_CR36","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: A randomized clinical trial. JAMA. 2016;315:2673\u201382.","journal-title":"JAMA"},{"key":"1123_CR37","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","volume":"71","author":"MA Cavender","year":"2018","unstructured":"Cavender MA, Norhammar A, Birkeland KI, J\u00f8rgensen ME, Wilding JP, Khunti K, et al. SGLT-2 inhibitors and cardiovascular risk: An analysis of CVD-REAL. J Am Coll Cardiol. 2018;71:2497\u2013506.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25:602\u201310.","journal-title":"Diabetes Obes Metab"},{"key":"1123_CR39","doi-asserted-by":"crossref","unstructured":"Bayes-Genis A, Cai A, Liu Y, Pandey A, Pop-Busui R, Hansen M, Januzzi JL. Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS. Eur J Heart Fail. 2025.","DOI":"10.1002\/ejhf.3786"},{"key":"1123_CR40","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","volume":"25","author":"A Bayes-Genis","year":"2023","unstructured":"Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25:1891\u20138.","journal-title":"Eur J Heart Fail"},{"key":"1123_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jacc.2025.06.041","volume":"86","author":"A Cai","year":"2025","unstructured":"Cai A, Liu L, Feng Y, Li L, Bozkurt B, Januzzi JL Jr., et al. Comparison of fixed vs age-adjusted NT-proBNP cutoffs to define pre-heart failure. J Am Coll Cardiol. 2025;86:625\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/ajh\/hpad065","volume":"36","author":"NR Daya","year":"2023","unstructured":"Daya NR, McEvoy JW, Christenson RH, Tang O, Foti K, Juraschek SP, et al. Prevalence of elevated NT-proBNP and its prognostic value by blood pressure treatment and control. Am J Hypertens. 2023;36:602\u201311.","journal-title":"Am J Hypertens"},{"key":"1123_CR43","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.119.043337","volume":"140","author":"A Pandey","year":"2019","unstructured":"Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC\/AHA high blood pressure guideline: A pooled cohort analysis. Circulation. 2019;140:2076\u201388.","journal-title":"Circulation"},{"key":"1123_CR44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","volume":"17","author":"JP Goetze","year":"2020","unstructured":"Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17:698\u2013717.","journal-title":"Nat Rev Cardiol"},{"key":"1123_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrcardio.2014.64","volume":"11","author":"NE Zois","year":"2014","unstructured":"Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11:403\u201312.","journal-title":"Nat Rev Cardiol"},{"key":"1123_CR46","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/cvr\/cvx183","volume":"113","author":"KC Park","year":"2017","unstructured":"Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113:1708\u201318.","journal-title":"Cardiovasc Res"},{"key":"1123_CR47","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrcardio.2017.48","volume":"14","author":"D Westermann","year":"2017","unstructured":"Westermann D, Neumann JT, S\u00f6rensen NA, Blankenberg S. High-sensitivity assays for troponin in patients with cardiac disease. Nat Rev Cardiol. 2017;14:472\u201383.","journal-title":"Nat Rev Cardiol"},{"key":"1123_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/01.RES.69.2.491","volume":"69","author":"Y Ogawa","year":"1991","unstructured":"Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991;69:491\u2013500.","journal-title":"Circ Res"},{"key":"1123_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/01.HYP.19.2.206","volume":"19","author":"M Kohno","year":"1992","unstructured":"Kohno M, Horio T, Yoshiyama M, Takeda T. Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension (Dallas, Tex. : 1979). 1992;19:206\u201311.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR50","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1161\/01.CIR.93.11.2059","volume":"93","author":"T Ogawa","year":"1996","unstructured":"Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation. 1996;93:2059\u201367.","journal-title":"Circulation"},{"key":"1123_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/HYPERTENSIONAHA.115.05610","volume":"66","author":"SJ Holditch","year":"2015","unstructured":"Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, et al. B-Type natriuretic peptide deletion leads to progressive hypertension, associated organ damage, and reduced survival: Novel model for human hypertension. Hypertension (Dallas, Tex. : 1979). 2015;66:199\u2013210.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9343(92)90011-Y","volume":"92","author":"M Kohno","year":"1992","unstructured":"Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29\u201334.","journal-title":"Am J Med"},{"key":"1123_CR53","first-page":"245","volume":"7","author":"MG Buckley","year":"1993","unstructured":"Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens. 1993;7:245\u201350.","journal-title":"J Hum Hypertens"},{"key":"1123_CR54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/ng.328","volume":"41","author":"C Newton-Cheh","year":"2009","unstructured":"Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348\u201353.","journal-title":"Nat Genet"},{"key":"1123_CR55","doi-asserted-by":"publisher","first-page":"e005257","DOI":"10.1161\/JAHA.116.005257","volume":"6","author":"SB Seidelmann","year":"2017","unstructured":"Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, et al. An NPPB promoter polymorphism associated with elevated N-Terminal pro-B-Type natriuretic peptide and lower blood pressure, hypertension, and mortality. J Am Heart Assoc. 2017;6:e005257.","journal-title":"J Am Heart Assoc"},{"key":"1123_CR56","doi-asserted-by":"publisher","first-page":"H1529","DOI":"10.1152\/ajpheart.00107.2006","volume":"291","author":"P Belluardo","year":"2006","unstructured":"Belluardo P, Cataliotti A, Bonaiuto L, Giuffr\u00e8 E, Maugeri E, Noto P, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291:H1529\u201335.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1123_CR57","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","volume":"60","author":"F Macheret","year":"2012","unstructured":"Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60:1558\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101678","volume":"4","author":"J Guo","year":"2025","unstructured":"Guo J, Liu Y, Liu X, Yan M, Zhang Y, Fang S, et al. Systolic and diastolic blood pressure, cardiac biomarkers, and cardiovascular mortality in adults without cardiovascular disease. JACC Adv. 2025;4:101678.","journal-title":"JACC Adv"},{"key":"1123_CR59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1161\/HYPERTENSIONAHA.113.02204","volume":"63","author":"P Welsh","year":"2014","unstructured":"Welsh P, Poulter NR, Chang CL, Sever PS, Sattar N. The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension (Dallas, Tex. : 1979). 2014;63:507\u201313.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR60","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1097\/HJH.0000000000000570","volume":"33","author":"M Satoh","year":"2015","unstructured":"Satoh M, Hosaka M, Asayama K, Kikuya M, Inoue R, Metoki H, et al. Association between N-terminal pro B-type natriuretic peptide and day-to-day blood pressure and heart rate variability in a general population: The Ohasama study. J Hypertens. 2015;33:1536\u201341.","journal-title":"J Hypertens"},{"key":"1123_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1524-6175.2007.07250.x","volume":"10","author":"J Ishikawa","year":"2008","unstructured":"Ishikawa J, Hoshide S, Shibasaki S, Matsui Y, Kabutoya T, Eguchi K, et al. Relationship between morning hypertension identified by home blood pressure monitoring and brain natriuretic peptide and estimated glomerular filtration rate: The Japan Morning Surge 1 (JMS-1) Study. J Clin Hypertens (Greenwich, Conn.). 2008;10:34\u201342.","journal-title":"J Clin Hypertens (Greenwich, Conn.)"},{"key":"1123_CR62","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/ajh\/hpu226","volume":"28","author":"S Aeschbacher","year":"2015","unstructured":"Aeschbacher S, Schoen T, Bossard M, van der Lely S, Gl\u00e4ttli K, Todd J, et al. Relationship between high-sensitivity cardiac troponin I and blood pressure among young and healthy adults. Am J Hypertens. 2015;28:789\u201396.","journal-title":"Am J Hypertens"},{"key":"1123_CR63","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","volume":"68","author":"JW McEvoy","year":"2016","unstructured":"McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: Implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR64","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MCA.0b013e328056dd33","volume":"18","author":"SM Dogan","year":"2007","unstructured":"Dogan SM, Aydin M, Gursurer M, Dursun A, Mungan G, Onuk T. N-terminal probrain natriuretic peptide predicts altered circadian variation in essential hypertension. Coron Artery Dis. 2007;18:347\u201352.","journal-title":"Coron Artery Dis"},{"key":"1123_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jch.12176","volume":"15","author":"M \u00c7ayl\u0131","year":"2013","unstructured":"\u00c7ayl\u0131 M, G\u00fcr M, Elbasan Z, \u015eeker T, T\u00fcrko\u011flu C, Kaypakl\u0131 O, et al. High-sensitivity cardiac troponin T predicts nondipper hypertension in newly diagnosed hypertensive patients. J Clin Hypertens (Greenwich, Conn.). 2013;15:731\u20136.","journal-title":"J Clin Hypertens (Greenwich, Conn.)"},{"key":"1123_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1291\/hypres.30.651","volume":"30","author":"T Nakatsu","year":"2007","unstructured":"Nakatsu T, Shinohata R, Mashima K, Yuki Y, Nishitani A, Toyonaga S, et al. Use of plasma B-type natriuretic peptide level to identify asymptomatic hypertensive patients with abnormal diurnal blood pressure variation profiles: nondippers, extreme dippers, and risers. Hypertens Res. 2007;30:651\u20138.","journal-title":"Hypertens Res"},{"key":"1123_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.112.197657","volume":"61","author":"ER Fox","year":"2013","unstructured":"Fox ER, Musani SK, Singh P, Bidulescu A, Nagarajarao HS, Samdarshi TE, et al. Association of plasma B-type natriuretic peptide concentrations with longitudinal blood pressure tracking in African Americans: findings from the Jackson Heart Study. Hypertension (Dallas, Tex. : 1979). 2013;61:48\u201354.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR68","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/ajh\/hpv026","volume":"28","author":"JK Bower","year":"2015","unstructured":"Bower JK, Lazo M, Matsushita K, Rubin J, Hoogeveen RC, Ballantyne CM, Selvin E. N-Terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens. 2015;28:1262\u20136.","journal-title":"Am J Hypertens"},{"key":"1123_CR69","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/HJH.0000000000000500","volume":"33","author":"OA Sanchez","year":"2015","unstructured":"Sanchez OA, Jacobs DR Jr., Bahrami H, Peralta CA, Daniels LB, Lima JA, et al. Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis. J Hypertens. 2015;33:966\u201374.","journal-title":"J Hypertens"},{"key":"1123_CR70","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.114.014364","volume":"132","author":"JW McEvoy","year":"2015","unstructured":"McEvoy JW, Chen Y, Nambi V, Ballantyne CM, Sharrett AR, Appel LJ, et al. High-Sensitivity cardiac troponin T and risk of hypertension. Circulation. 2015;132:825\u201333.","journal-title":"Circulation"},{"key":"1123_CR71","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1373\/clinchem.2017.275289","volume":"63","author":"A Jagodzinski","year":"2017","unstructured":"Jagodzinski A, Neumann JT, Ojeda F, S\u00f6rensen NA, Wild P, M\u00fcnzel T, et al. Cardiovascular biomarkers in hypertensive patients with medical treatment-results from the randomized TEAMSTA protect I trial. Clin Chem. 2017;63:1877\u201385.","journal-title":"Clin Chem"},{"key":"1123_CR72","doi-asserted-by":"crossref","unstructured":"Berry JD, Chen H, Nambi V, Ambrosius WT, Ascher SB, Shlipak MG et al. Effect of intensive blood pressure control on troponin and natriuretic peptide levels: Findings from SPRINT. Circulation 2023;147:310\u201323.","DOI":"10.1161\/CIRCULATIONAHA.122.059960"},{"key":"1123_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/A:1011027231702","volume":"216","author":"V Raizada","year":"2001","unstructured":"Raizada V, Thakore K, Luo W, McGuire PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem. 2001;216:137\u201340.","journal-title":"Mol Cell Biochem"},{"key":"1123_CR74","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1161\/CIRCULATIONAHA.110.981720","volume":"123","author":"A Cataliotti","year":"2011","unstructured":"Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011;123:1297\u2013305.","journal-title":"Circulation"},{"key":"1123_CR75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1161\/01.HYP.28.1.22","volume":"28","author":"T Nishikimi","year":"1996","unstructured":"Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension (Dallas, Tex. : 1979). 1996;28:22\u201330.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR76","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/00004872-200018080-00018","volume":"18","author":"A Luchner","year":"2000","unstructured":"Luchner A, Burnett JC Jr., Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121\u20138.","journal-title":"J Hypertens"},{"key":"1123_CR77","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijcard.2003.10.015","volume":"97","author":"P Uusimaa","year":"2004","unstructured":"Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J, et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol. 2004;97:251\u20136.","journal-title":"Int J Cardiol"},{"key":"1123_CR78","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.jacc.2017.10.044","volume":"70","author":"CY Liu","year":"2017","unstructured":"Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, et al. Association of Elevated NT-proBNP with myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2017;70:3102\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0167-5273(99)00023-6","volume":"69","author":"P Bettencourt","year":"1999","unstructured":"Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brand\u00e3o F, Pol\u00f3nia J, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol. 1999;69:169\u201377.","journal-title":"Int J Cardiol"},{"key":"1123_CR80","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0002-9343(99)80372-6","volume":"98","author":"M Kohno","year":"1995","unstructured":"Kohno M, Horio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med. 1995;98:257\u201365.","journal-title":"Am J Med"},{"key":"1123_CR81","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.amjhyper.2003.07.024","volume":"16","author":"M Nakamura","year":"2003","unstructured":"Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens. 2003;16:1025\u20139.","journal-title":"Am J Hypertens"},{"key":"1123_CR82","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.cca.2011.02.035","volume":"412","author":"E Di Stasio","year":"2011","unstructured":"Di Stasio E, Russo A, Mettimano M, Viviani D, Scagliusi A, Bruno A, et al. NT-proBNP: A marker of preclinical cardiac damage in arterial hypertension. Clin Chim Acta. 2011;412:1106\u201311.","journal-title":"Clin Chim Acta"},{"key":"1123_CR83","first-page":"532","volume":"1","author":"M Siciliano","year":"2000","unstructured":"Siciliano M, Mettimano M, Dondolini-Poli A, Ballarin S, Migneco A, Annese R, et al. Troponin I serum concentration: A new marker of left ventricular hypertrophy in patients with essential hypertension. Ital Heart J. 2000;1:532\u20135.","journal-title":"Ital Heart J"},{"key":"1123_CR84","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.4238\/2014.July.7.7","volume":"13","author":"DM Miao","year":"2014","unstructured":"Miao DM, Zhang LP, Yu HP, Zhang JY, Xiao WK, Ye P. Serum levels of high-sensitivity troponin T: A novel marker for left ventricular remodeling and performance in hypertensive subjects. Genet Mol Res: GMR. 2014;13:5143\u201353.","journal-title":"Genet Mol Res: GMR"},{"key":"1123_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/08037051.2013.840429","volume":"23","author":"H U\u00e7ar","year":"2014","unstructured":"U\u00e7ar H, G\u00fcr M, Kivrak A, Koyunsever NY, Seker T, Akilli RE, et al. High-sensitivity cardiac troponin T levels in newly diagnosed hypertensive patients with different left ventricle geometry. Blood Press. 2014;23:240\u20137.","journal-title":"Blood Press"},{"key":"1123_CR86","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1161\/CIRCULATIONAHA.116.025505","volume":"135","author":"SL Seliger","year":"2017","unstructured":"Seliger SL, Hong SN, Christenson RH, Kronmal R, Daniels LB, Lima JAC, et al. High-sensitive cardiac troponin t as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). Circulation. 2017;135:1494\u2013505.","journal-title":"Circulation"},{"key":"1123_CR87","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1001\/jamacardio.2019.3113","volume":"4","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Claggett B, Ballantyne CM, Selvin E, R\u00f8sj\u00f8 H, Omland T, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and incident heart failure in older adults. JAMA Cardiol. 2019;4:997\u20131006.","journal-title":"JAMA Cardiol"},{"key":"1123_CR88","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/joim.12023","volume":"273","author":"S Masson","year":"2013","unstructured":"Masson S, Latini R, Mureddu GF, Agabiti N, Miceli M, Cesaroni G, et al. High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. J Intern Med Suppl. 2013;273:306\u201317.","journal-title":"J Intern Med Suppl"},{"key":"1123_CR89","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/clinchem\/hvaa023","volume":"66","author":"MN Lyngbakken","year":"2020","unstructured":"Lyngbakken MN, Aagaard EN, Kvisvik B, Berge T, Pervez MO, Brynildsen J, et al. Cardiac troponin I and T are associated with left ventricular function and structure: data from the akershus cardiac examination 1950 study. Clin Chem. 2020;66:567\u201378.","journal-title":"Clin Chem"},{"key":"1123_CR90","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1291\/hypres.25.669","volume":"25","author":"M Suzuki","year":"2002","unstructured":"Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res. 2002;25:669\u201376.","journal-title":"Hypertens Res"},{"key":"1123_CR91","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1097\/01.hjh.0000125451.28861.2a","volume":"22","author":"MH Olsen","year":"2004","unstructured":"Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study. J Hypertens. 2004;22:1597\u2013604.","journal-title":"J Hypertens"},{"key":"1123_CR92","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1097\/01.hjh.0000239288.10013.04","volume":"24","author":"MH Olsen","year":"2006","unstructured":"Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy. J Hypertens. 2006;24:1531\u20139.","journal-title":"J Hypertens"},{"key":"1123_CR93","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.cardfail.2005.04.015","volume":"11","author":"F Pedersen","year":"2005","unstructured":"Pedersen F, Raymond I, Kistorp C, Sandgaard N, Jacobsen P, Hildebrandt P. N-terminal pro-brain natriuretic peptide in arterial hypertension: A valuable prognostic marker of cardiovascular events. J Card Fail. 2005;11:S70\u20135.","journal-title":"J Card Fail"},{"key":"1123_CR94","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1161\/HYPERTENSIONAHA.110.163550","volume":"57","author":"V Paget","year":"2011","unstructured":"Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, et al. N-terminal pro-brain natriuretic peptide: A powerful predictor of mortality in hypertension. Hypertension (Dallas, Tex. : 1979). 2011;57:702\u20139.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR95","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jchf.2014.12.018","volume":"3","author":"SL Seliger","year":"2015","unstructured":"Seliger SL, de Lemos J, Neeland IJ, Christenson R, Gottdiener J, Drazner MH, et al. Older Adults, \u201cMalignant\u201d Left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). JACC Heart Failure. 2015;3:445\u201355.","journal-title":"JACC Heart Failure"},{"key":"1123_CR96","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1161\/CIRCULATIONAHA.119.043628","volume":"141","author":"AA Lewis","year":"2020","unstructured":"Lewis AA, Ayers CR, Selvin E, Neeland I, Ballantyne CM, Nambi V, et al. Racial differences in malignant left ventricular hypertrophy and incidence of heart failure: A multicohort study. Circulation. 2020;141:957\u201367.","journal-title":"Circulation"},{"key":"1123_CR97","doi-asserted-by":"publisher","first-page":"e006619","DOI":"10.1161\/JAHA.117.006619","volume":"7","author":"MN Peters","year":"2018","unstructured":"Peters MN, Seliger SL, Christenson RH, Hong-Zohlman SN, Daniels LB, Lima JAC, et al. \u201cMalignant\u201d left ventricular hypertrophy identifies subjects at high risk for progression to asymptomatic left ventricular dysfunction, heart failure, and death: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018;7:e006619.","journal-title":"J Am Heart Assoc"},{"key":"1123_CR98","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijcard.2018.09.028","volume":"276","author":"ML Topel","year":"2019","unstructured":"Topel ML, Sandesara PB, Stahl EP, Hayek SS, Tahhan AS, O\u2019Neal WT, et al. Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation. Int J Cardiol. 2019;276:255\u201360.","journal-title":"Int J Cardiol"},{"key":"1123_CR99","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1097\/HJH.0b013e3283599b4f","volume":"30","author":"DJ Pattanshetty","year":"2012","unstructured":"Pattanshetty DJ, Bhat PK, Aneja A, Pillai DP. Elevated troponin predicts long-term adverse cardiovascular outcomes in hypertensive crisis: A retrospective study. J Hypertens. 2012;30:2410\u20135.","journal-title":"J Hypertens"},{"key":"1123_CR100","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41440-023-01468-8","volume":"47","author":"H Watanabe","year":"2024","unstructured":"Watanabe H, Hoshide S, Kanegae H, Kario K. Prognosis of a malignant phenotype of obesity defined by a cardiac biomarker in hypertension: the Japan Morning Surge-Home Blood Pressure study. Hypertens Res. 2024;47:487\u201395.","journal-title":"Hypertens Res"},{"key":"1123_CR101","doi-asserted-by":"publisher","first-page":"311","DOI":"10.18632\/aging.100655","volume":"6","author":"JM Tonne","year":"2014","unstructured":"Tonne JM, Holditch SJ, Oehler EA, Schreiber CA, Ikeda Y, Cataliotti A. Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. Aging. 2014;6:311\u20139.","journal-title":"Aging"},{"key":"1123_CR102","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jacc.2012.10.012","volume":"61","author":"IJ Neeland","year":"2013","unstructured":"Neeland IJ, Drazner MH, Berry JD, Ayers CR, deFilippi C, Seliger SL, et al. Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population. J Am Coll Cardiol. 2013;61:187\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR103","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamacardio.2018.4300","volume":"4","author":"A Pandey","year":"2019","unstructured":"Pandey A, Keshvani N, Ayers C, Correa A, Drazner MH, Lewis A, et al. Association of cardiac injury and malignant left ventricular hypertrophy with risk of heart failure in african americans: the jackson heart study. JAMA Cardiol. 2019;4:51\u201358.","journal-title":"JAMA Cardiol"},{"key":"1123_CR104","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.114.04206","volume":"65","author":"Y Pokharel","year":"2015","unstructured":"Pokharel Y, Sun W, de Lemos JA, Taffet GE, Virani SS, Ndumele CE, et al. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: Atherosclerosis risk in communities study. Hypertension (Dallas, Tex. : 1979). 2015;65:78\u201384.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR105","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1373\/clinchem.2013.203638","volume":"59","author":"V Nambi","year":"2013","unstructured":"Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: A biomarker approach to predict heart failure risk\u2013the atherosclerosis risk in communities study. Clin Chem. 2013;59:1802\u201310.","journal-title":"Clin Chem"},{"key":"1123_CR106","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2020.11.063","volume":"77","author":"A Hussain","year":"2021","unstructured":"Hussain A, Sun W, Deswal A, de Lemos JA, McEvoy JW, Hoogeveen RC, et al. Association of NT-ProBNP, blood pressure, and cardiovascular events: The ARIC study. J Am Coll Cardiol. 2021;77:559\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR107","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/HYPERTENSIONAHA.123.22665","volume":"81","author":"K Foti","year":"2024","unstructured":"Foti K, Wang D, Tang O, Daya NR, Commodore-Mensah Y, Juraschek SP, et al. Modeling the Impact of Biomarker-Guided Versus ASCVD risk-guided drug treatment in US adults with Stage 1 hypertension: The national health and nutrition examination survey, 1999 to 2004. Hypertension (Dallas, Tex. : 1979). 2024;81:1599\u2013608.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR108","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","volume":"6","author":"JD Berry","year":"2021","unstructured":"Berry JD, Nambi V, Ambrosius WT, Chen H, Killeen AA, Taylor A, et al. Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: Findings from the SPRINT randomized clinical trial. JAMA Cardiol. 2021;6:1397\u2013405.","journal-title":"JAMA Cardiol"},{"key":"1123_CR109","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.jacc.2022.08.735","volume":"80","author":"SB Ascher","year":"2022","unstructured":"Ascher SB, de Lemos JA, Lee M, Wu E, Soliman EZ, Neeland IJ, et al. Intensive blood pressure lowering in patients with malignant left ventricular hypertrophy. J Am Coll Cardiol. 2022;80:1516\u201325.","journal-title":"J Am Coll Cardiol"},{"key":"1123_CR110","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/CIRCULATIONAHA.125.076263","volume":"152","author":"A Cai","year":"2025","unstructured":"Cai A, Bayes-Genis A, Ryan J, Feng Y, Januzzi JL, Tonkin AM, et al. Heart stress and blood pressure management in older adults: Post Hoc analysis of the ASPREE trial. Circulation. 2025;152:1621\u201333.","journal-title":"Circulation"},{"key":"1123_CR111","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0895-7061(98)00116-2","volume":"11","author":"ML Kuroski de Bold","year":"1998","unstructured":"Kuroski de Bold ML. Atrial natriuretic factor and brain natriuretic peptide gene expression in the spontaneous hypertensive rat during postnatal development. Am J Hypertens. 1998;11:1006\u201318.","journal-title":"Am J Hypertens"},{"key":"1123_CR112","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000066319","volume":"98","author":"S Almeida","year":"2002","unstructured":"Almeida S, Azevedo A, Castro A, Fri\u00f5es F, Freitas J, Ferreira A, Bettencourt P. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology. 2002;98:113\u20135.","journal-title":"Cardiology"},{"key":"1123_CR113","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/08037050601037760","volume":"15","author":"P Jakubik","year":"2006","unstructured":"Jakubik P, Janota T, Widimsky J Jr., Zelinka T, Strauch B, Petrak O, et al. Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentration. Blood Press. 2006;15:302\u20137.","journal-title":"Blood Press"},{"key":"1123_CR114","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jjcc.2011.07.009","volume":"58","author":"Y Sato","year":"2011","unstructured":"Sato Y, Yamamoto E, Sawa T, Toda K, Hara T, Iwasaki T, et al. High-sensitivity cardiac troponin T in essential hypertension. J Cardiol. 2011;58:226\u201331.","journal-title":"J Cardiol"},{"key":"1123_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43278-4","volume":"9","author":"TH Hidru","year":"2019","unstructured":"Hidru TH, Yang X, Xia Y, Ma L, Li HH. The relationship between plasma markers and essential hypertension in middle-aged and elderly chinese population: A community based cross-sectional study. Sci Rep. 2019;9:6813.","journal-title":"Sci Rep"},{"key":"1123_CR116","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.amjcard.2019.04.030","volume":"124","author":"N Madan","year":"2019","unstructured":"Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E, McEvoy JW. Relation of isolated systolic hypertension and pulse pressure to high-sensitivity cardiac Troponin-T and N-Terminal pro-B-Type natriuretic peptide in older adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019;124:245\u201352.","journal-title":"Am J Cardiol"},{"key":"1123_CR117","doi-asserted-by":"publisher","first-page":"e031107","DOI":"10.1161\/JAHA.123.031107","volume":"13","author":"J Young","year":"2024","unstructured":"Young J, Lyngbakken MN, Hveem K, R\u00f8sj\u00f8 H, Omland T. Systolic blood pressure, diastolic blood pressure and pulse pressure and the risk of subclinical myocardial injury: The HUNT study. J Am Heart Assoc. 2024;13:e031107.","journal-title":"J Am Heart Assoc"},{"key":"1123_CR118","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/01.HYP.0000061116.20490.8D","volume":"41","author":"MH Freitag","year":"2003","unstructured":"Freitag MH, Larson MG, Levy D, Benjamin EJ, Wang TJ, Leip EP, et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension (Dallas, Tex. : 1979). 2003;41:978\u201383.","journal-title":"Hypertension (Dallas, Tex. : 1979)"},{"key":"1123_CR119","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1291\/hypres.31.1737","volume":"31","author":"H Takase","year":"2008","unstructured":"Takase H, Dohi Y, Toriyama T, Okado T, Tanaka S, Sato K, Kimura G. Does B-type natriuretic peptide predict the new onset of hypertension? Hypertens Res. 2008;31:1737\u201344.","journal-title":"Hypertens Res"},{"key":"1123_CR120","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/2047487316683070","volume":"24","author":"PY Courand","year":"2017","unstructured":"Courand PY, Harbaoui B, B\u00e8cle C, Mouly-Bertin C, Lantelme P. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension. Eur J Prev Cardiol. 2017;24:452\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"1123_CR121","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0026-0495(96)90110-9","volume":"45","author":"M Kohno","year":"1996","unstructured":"Kohno M, Yasunari K, Yokokawa K, Horio T, Kano H, Minami M, et al. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy. Metabolism. 1996;45:1326\u20139.","journal-title":"Metabolism"},{"key":"1123_CR122","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1440-1681.1997.tb02729.x","volume":"24","author":"BM Cheung","year":"1997","unstructured":"Cheung BM. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol. 1997;24:966\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1123_CR123","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0002-9343(00)00364-8","volume":"108","author":"M Suzuki","year":"2000","unstructured":"Suzuki M, Yamamoto K, Watanabe S, Iwata T, Hamada M, Hiwada K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med. 2000;108:627\u201333.","journal-title":"Am J Med"},{"key":"1123_CR124","first-page":"278","volume":"83","author":"S Talwar","year":"2000","unstructured":"Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart (British Cardiac Society). 2000;83:278\u201382.","journal-title":"Heart (British Cardiac Society)"},{"key":"1123_CR125","first-page":"327","volume":"22","author":"P Almeida","year":"2003","unstructured":"Almeida P, Azevedo A, Rodrigues R, Dias P, Fri\u00f5es F, Vazquez B, et al. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol. 2003;22:327\u201336.","journal-title":"Rev Port Cardiol"},{"key":"1123_CR126","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejheart.2004.01.001","volume":"6","author":"P Hildebrandt","year":"2004","unstructured":"Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension\u2013a marker for left ventricular dimensions and prognosis. Eur J Heart Fail. 2004;6:313\u20137.","journal-title":"Eur J Heart Fail"},{"key":"1123_CR127","doi-asserted-by":"publisher","first-page":"73s","DOI":"10.1016\/j.amjhyper.2004.11.044","volume":"18","author":"V Bhalla","year":"2005","unstructured":"Bhalla V, Isakson S, Bhalla MA, Lin JP, Clopton P, Gardetto N, Maisel AS. Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients. Am J Hypertens. 2005;18:73s\u201381s.","journal-title":"Am J Hypertens"},{"key":"1123_CR128","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1373\/clinchem.2005.056648","volume":"51","author":"T Mueller","year":"2005","unstructured":"Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem. 2005;51:2245\u201351.","journal-title":"Clin Chem"},{"key":"1123_CR129","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejheart.2004.03.015","volume":"7","author":"T Wei","year":"2005","unstructured":"Wei T, Zeng C, Chen L, Chen Q, Zhao R, Lu G, et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail. 2005;7:75\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1123_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.jhh.1001988","volume":"20","author":"D Conen","year":"2006","unstructured":"Conen D, Pfisterer M, Martina B. Substantial intraindividual variability of BNP concentrations in patients with hypertension. J Hum Hypertens. 2006;20:387\u201391.","journal-title":"J Hum Hypertens"},{"key":"1123_CR131","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/10641960701361593","volume":"29","author":"R Irzma\u0144ski","year":"2007","unstructured":"Irzma\u0144ski R, Banach M, Piechota M, Kowalski J, Barylski M, Cierniewski C, Pawlicki L. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin Exp Hypertens (New York, N.Y. : 1993). 2007;29:149\u201364.","journal-title":"Clin Exp Hypertens (New York, N.Y. : 1993)"},{"key":"1123_CR132","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1157\/13125520","volume":"61","author":"P Morillas","year":"2008","unstructured":"Morillas P, Castillo J, Quiles J, Nu\u00f1ez D, Guill\u00e9n S, Maceira A, et al. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study. Rev Esp Cardiol. 2008;61:972\u20135.","journal-title":"Rev Esp Cardiol"},{"key":"1123_CR133","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.acvd.2008.04.007","volume":"101","author":"C Mouly-Bertin","year":"2008","unstructured":"Mouly-Bertin C, Bissery A, Milon H, Dzudie A, Rabilloud M, Bricca G, et al. N-terminal pro-brain natriuretic peptide\u2013a promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women. Arch Cardiovasc Dis. 2008;101:307\u201315.","journal-title":"Arch Cardiovasc Dis"},{"key":"1123_CR134","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ahj.2008.12.017","volume":"157","author":"JA de Lemos","year":"2009","unstructured":"de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study. Am Heart J. 2009;157:746\u201353.e2.","journal-title":"Am Heart J"},{"key":"1123_CR135","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/08037050903083298","volume":"18","author":"M Magnusson","year":"2009","unstructured":"Magnusson M, Jovinge S, Rydberg E, Dahl\u00f6f B, Hall C, Nielsen OW, et al. Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients. Blood Press. 2009;18:196\u2013203.","journal-title":"Blood Press"},{"key":"1123_CR136","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1016\/j.ijcard.2013.07.260","volume":"168","author":"A Iacovoni","year":"2013","unstructured":"Iacovoni A, De Maria R, Gavazzi A, Grosu A, Fontana A, Guideri S, et al. Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. Int J Cardiol. 2013;168:5093\u20135.","journal-title":"Int J Cardiol"},{"key":"1123_CR137","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1536\/ihj.52.164","volume":"52","author":"K Setsuta","year":"2011","unstructured":"Setsuta K, Kitahara Y, Arae M, Ohbayashi T, Seino Y, Mizuno K. Elevated cardiac troponin T predicts adverse outcomes in hypertensive patients. Int Heart J. 2011;52:164\u20139.","journal-title":"Int Heart J"},{"key":"1123_CR138","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/HJH.0b013e32835eb5e8","volume":"31","author":"ME Hellemons","year":"2013","unstructured":"Hellemons ME, Lambers Heerspink HJ, Gansevoort RT, de Zeeuw D, Bakker SJ. High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case-control study with confirmation in diabetes. J Hypertens. 2013;31:805\u201312.","journal-title":"J Hypertens"},{"key":"1123_CR139","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/ajh\/hpz102","volume":"32","author":"DM Tehrani","year":"2019","unstructured":"Tehrani DM, Fan W, Nambi V, Gardin J, Hirsch CH, Amsterdam E, et al. Trends in blood pressure and high-sensitivity cardiac Troponin-T with cardiovascular disease: The cardiovascular health study. Am J Hypertens. 2019;32:1013\u201320.","journal-title":"Am J Hypertens"},{"key":"1123_CR140","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/2047487319899618","volume":"28","author":"M Gori","year":"2021","unstructured":"Gori M, Lam CSP, D\u2019Elia E, Iorio AM, Calabrese A, Canova P, et al. Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. Eur J Prev Cardiol. 2021;28:937\u201345.","journal-title":"Eur J Prev Cardiol"},{"key":"1123_CR141","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032493","volume":"13","author":"C Smith","year":"2024","unstructured":"Smith C, Berry JD, Scherzer R, de Lemos JA, Nambi V, Ballantyne CM, et al. Intensive blood pressure lowering in individuals with low diastolic blood pressure and elevated troponin levels in SPRINT. J Am Heart Assoc. 2024;13:e032493.","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01123-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01123-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:02:13Z","timestamp":1775847733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01123-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":141,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01123-y","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}